KDM6A and chronic myelogenous leukemia, BCR-ABL1 positive: Similar to these findings in K562 and MEG-01 cells, knockdown of KDM6A in KU812 CML cells as well as the imatinib-resistant K562/G01 subline was able to abrogate the protective effects of NGF after treatment with imatinib (Figure S7A-C and Figure S7D-F, respectively).